Flash e-reader

 Go to e-reader chapter








Table 14.6

De Novo Posttransplant Solid Malignancy, 2000 to 2009

Kidney Recipients

Malignancies by Type Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Total # of Post-Tx Malignancies 1,278 1,239 1,133 1,138 1,115 999 894 583 381 189
Squamous/Basal Cell Carcinoma 660 640 587 588 575 468 476 302 203 109
Melanoma 41 31 35 35 32 25 35 21 18 5
Kaposi Sarcoma 10 8 2 5 8 6 5 2 7 -
Central Nervous System 12 12 11 7 6 11 10 3 1 3
Genito-Urinary (1) 185 174 182 169 171 174 123 97 52 28
Gastro-Intestinal (2) 87 80 68 69 80 73 68 44 30 9
Primary Hepatic Tumor 12 10 9 6 15 11 9 12 7 2
Metastatic Hepatic Tumor 13 23 16 15 13 16 11 6 3 2
Larynx/Bronchi/Lung 99 112 94 97 101 96 68 28 23 8
Breast/Thyroid 72 67 59 79 55 57 36 38 17 14
Leukemia 6 9 11 4 10 7 3 2 5 2
Sarcoma (3) 4 6 - 6 6 1 3 5 1 -
Other 62 57 47 43 40 44 40 21 12 6
Unknown 15 10 12 15 3 10 7 2 2 1
Squamous/Basal Cell Carcinoma 51.6% 51.7% 51.8% 51.7% 51.6% 46.8% 53.2% 51.8% 53.3% 57.7%
Melanoma 3.2% 2.5% 3.1% 3.1% 2.9% 2.5% 3.9% 3.6% 4.7% 2.6%
Kaposi Sarcoma 0.8% 0.6% 0.2% 0.4% 0.7% 0.6% 0.6% 0.3% 1.8% -
Central Nervous System 0.9% 1.0% 1.0% 0.6% 0.5% 1.1% 1.1% 0.5% 0.3% 1.6%
Genito-Urinary (1) 14.5% 14.0% 16.1% 14.9% 15.3% 17.4% 13.8% 16.6% 13.6% 14.8%
Gastro-Intestinal (2) 6.8% 6.5% 6.0% 6.1% 7.2% 7.3% 7.6% 7.5% 7.9% 4.8%
Primary Hepatic Tumor 0.9% 0.8% 0.8% 0.5% 1.3% 1.1% 1.0% 2.1% 1.8% 1.1%
Metastatic Hepatic Tumor 1.0% 1.9% 1.4% 1.3% 1.2% 1.6% 1.2% 1.0% 0.8% 1.1%
Larynx/Bronchi/Lung 7.7% 9.0% 8.3% 8.5% 9.1% 9.6% 7.6% 4.8% 6.0% 4.2%
Breast/Thyroid 5.6% 5.4% 5.2% 6.9% 4.9% 5.7% 4.0% 6.5% 4.5% 7.4%
Leukemia 0.5% 0.7% 1.0% 0.4% 0.9% 0.7% 0.3% 0.3% 1.3% 1.1%
Sarcoma (3) 0.3% 0.5% - 0.5% 0.5% 0.1% 0.3% 0.9% 0.3% -
Other 4.9% 4.6% 4.1% 3.8% 3.6% 4.4% 4.5% 3.6% 3.1% 3.2%
Unknown 1.2% 0.8% 1.1% 1.3% 0.3% 1.0% 0.8% 0.3% 0.5% 0.5%
Total # of Patients 846 841 800 808 794 741 667 447 309 162


Source: OPTN/SRTR Data as of October 1, 2010.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.